A196170 Stock Overview
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALTEOGEN Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩387,000.00 |
| 52 Week High | ₩459,500.00 |
| 52 Week Low | ₩158,900.00 |
| Beta | 1.34 |
| 1 Month Change | -1.28% |
| 3 Month Change | 25.85% |
| 1 Year Change | 125.92% |
| 3 Year Change | 776.23% |
| 5 Year Change | 1,420.96% |
| Change since IPO | 12,860.00% |
Recent News & Updates
Shareholder Returns
| A196170 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 15.4% | -0.2% | -1.0% |
| 1Y | 125.9% | 16.7% | -11.5% |
Return vs Industry: A196170 exceeded the KR Biotechs industry which returned 16.7% over the past year.
Return vs Market: A196170 exceeded the KR Market which returned -11.5% over the past year.
Price Volatility
| A196170 volatility | |
|---|---|
| A196170 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.5% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A196170 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A196170's weekly volatility (9%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 138 | Soon-Jae Park | www.alteogen.com |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.
ALTEOGEN Inc. Fundamentals Summary
| A196170 fundamental statistics | |
|---|---|
| Market cap | ₩19.96t |
| Earnings (TTM) | ₩62.25b |
| Revenue (TTM) | ₩102.85b |
331.3x
P/E Ratio200.5x
P/S RatioIs A196170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A196170 income statement (TTM) | |
|---|---|
| Revenue | ₩102.85b |
| Cost of Revenue | ₩38.81b |
| Gross Profit | ₩64.04b |
| Other Expenses | ₩1.79b |
| Earnings | ₩62.25b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.17k |
| Gross Margin | 62.26% |
| Net Profit Margin | 60.52% |
| Debt/Equity Ratio | 3.1% |
How did A196170 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 10:21 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALTEOGEN Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyerin Lee | DAOL Investment & Securities Co., Ltd. |
| null null | DBS Bank Ltd |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |